BALTIMORE, MD--(Marketwired - Sep 10, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that Plandaí Biotechnology, Inc. (
Last week, the Company announced that it signed an exclusive agreement with North-West University in South Africa which holds the patents and associated intellectual property covering the entrapment of compounds in long-chain fatty acids-based nano- and micro-particles, known as Pheroid. Under the terms of the world license, Plandai has the exclusive right to use the Pheroid technology with all Phytofare™ polyene-based extracts, which includes proprietary extracts of most botanical matter, for human and animal use.
The primary feature of the Pheroid technology is the encapsulation application, which will dramatically enhance the Company's industry-leading bioavailability. The Pheroid technology, which can be delivered through different media, improves the absorption of the encapsulated contents while protecting the contents. It is actively used worldwide and has been extensively tested in humans and animals where it has shown an ability to significantly increase the level of absorption of the entrapped particles into the bloodstream.
The technology will enable the Company to produce its Phytofare™ topical products with significantly enhanced tissue absorption and oral products that can help Phytofare™ survive intact on its passage through the digestive tract and into the bloodstream. Once in the bloodstream, human cells perceive the Pheroid material as a biological building block and as a source of energy, allowing it to pass through the cell membrane and release the valuable phytonutrients (encapsulated contents) directly to the tissues.
The bottom line is that through the incorporation of the licensed technology, Plandai may be one of the first firms in the space to have the capability to consistently deliver products such as botanical extracts, including catechins, carotenoids, and citrus bioflavonoids and limonoids, to the target site in the most efficient and bioavailable form.
Given the low-hanging fruit of the topical product's efficacy and the size of the weight loss market, we believe that the Company will be able to market the combined product with great success beginning in 1H14, following the completion of a short trial. Products in other forms and targeting other markets will shortly follow, thus making 2014 the year that the Company migrates from the development stage to the marketing stage.
Goldman Small Cap Research articles, reports, and updates on Plandai as well as associated disclaimers and disclosures can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (
- Investment & Company Information